Identification

Name
Cyclobenzaprine
Accession Number
DB00924  (APRD00213)
Type
Small Molecule
Groups
Approved
Description

Cyclobenzaprine is a skeletal muscle relaxant and a central nervous system (CNS) depressant. Cyclobenzaprine acts on the locus coeruleus where it results in increased norepinephrine release, potentially through the gamma fibers which innervate and inhibit the alpha motor neurons in the ventral horn of the spinal cord. It is structurally similar to Amitriptyline, differing by only one double bond.

Structure
Thumb
Synonyms
  • (3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-amine
  • Ciclobenzaprina
  • Cyclobenzaprine
  • Cyclobenzaprinum
  • N,N-Dimethyl-5H-dibenzo(a,D)cycloheptene-delta(5,gamma)-propylamine
  • N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine
External IDs
TNX-102
Product Ingredients
IngredientUNIICASInChI Key
Cyclobenzaprine Hydrochloride0VE05JYS2P6202-23-9VXEAYBOGHINOKW-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Alti-cyclobenzaprine - Tab 10mgTablet10 mgOralAltimed Pharma Inc.1995-12-312005-05-27Canada
AmrixCapsule, extended release30 mg/1OralRebel Distributors2007-10-01Not applicableUs63459 0701 60 nlmimage10 602d3019
AmrixCapsule, extended release15 mg/1OralA S Medication Solutions2007-10-012017-06-20Us
AmrixCapsule, extended release15 mg/1OralA S Medication Solutions2007-10-022017-06-20Us
AmrixCapsule, extended release15 mg/1OralRebel Distributors2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralCephalon2007-10-01Not applicableUs
AmrixCapsule, extended release30 mg/1OralLake Erie Medical &Surgical Supply Dba Quality Care Products Llc2007-10-012017-11-07Us
AmrixCapsule, extended release15 mg/1OralStat Rx USA2007-10-01Not applicableUs
AmrixCapsule, extended release30 mg/1OralCephalon2007-10-01Not applicableUs
AmrixCapsule, extended release15 mg/1OralPhysicians Total Care, Inc.2009-04-16Not applicableUs63459 0700 60 nlmimage10 572d2b99
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-cyclobenzaprineTablet10 mgOralApotex Corporation1995-12-31Not applicableCanada
Comfort Pac With CyclobenzaprineKitPd Rx Pharmaceuticals, Inc.2013-07-15Not applicableUs
CyclobenzaprineTablet, film coated5 mg/1OralDirectrx2016-12-16Not applicableUs
CyclobenzaprineTablet, film coated7.5 mg/1OralCitron Pharma LLC2016-10-18Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralContract Pharmacy Services Pa2017-09-28Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralAmerincan Health Packaging2014-05-30Not applicableUs10702 0006 01 nlmimage10 1f3a0fa0
Cyclobenzaprine HydrochlorideTablet5 mg/1OralKaiser Foundations Hospitals2015-11-10Not applicableUs
Cyclobenzaprine HydrochlorideTablet5 mg/1OralKeltman Pharmaceuticals Inc.2010-06-10Not applicableUs
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralMajor1988-02-29Not applicableUs00904 7809 60 nlmimage10 d9346c83
Cyclobenzaprine HydrochlorideTablet, film coated5 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2007-02-28Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cyclobenzaprine HydrochlorideTablet, film coated10 mg/1OralH. J Harkins Company Inc2017-01-03Not applicableUs52959 04220171116 19895 19ljtli
Cyclobenzaprine HydrochlorideTablet, film coated7.5 mg/1OralProficient Rx LP2017-08-01Not applicableUs
Cyclobenzaprine HydrochlorideCapsule, film coated, extended release10 mg/1OralSterling Knight Pharmaceuticals, Llc2016-10-31Not applicableUs
TabradolKitOralFusion Pharmaceuticals LLC2009-09-17Not applicableUs
TabradolKitOralCalifornia Pharmaceuticals, Llc2016-01-01Not applicableUs
International/Other Brands
Flexeril (Janssen) / Flexiban (SIT)
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Cyclo/MagCyclobenzaprine Hydrochloride + Magnesium oxideKitLiving Well Pharmacy, Inc.2010-03-09Not applicableUs
Cyclo/Mag 10mg/200mgCyclobenzaprine Hydrochloride + Magnesium oxideKitLiving Well Pharmacy, Inc.2010-02-17Not applicableUs
Gapeam BudibacCyclobenzaprine Hydrochloride + Amantadine hydrochloride + Baclofen + Bupivacaine hydrochloride + Diclofenac sodium + Gabapentin + PentoxifyllineKitTopicalAlvix Laboratories2014-12-05Not applicableUs
Therabenzaprine-60Cyclobenzaprine Hydrochloride + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-05-152016-10-13Us
Therabenzaprine-90Cyclobenzaprine Hydrochloride + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-162016-10-13Us
Therabenzaprine-90-5Cyclobenzaprine Hydrochloride + gamma-Aminobutyric acidKitPhysician Therapeutics Llc2011-02-152016-10-13Us
Categories
UNII
69O5WQQ5TI
CAS number
303-53-7
Weight
Average: 275.3874
Monoisotopic: 275.167399677
Chemical Formula
C20H21N
InChI Key
JURKNVYFZMSNLP-UHFFFAOYSA-N
InChI
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3
IUPAC Name
dimethyl(3-{tricyclo[9.4.0.0³,⁸]pentadeca-1(15),3,5,7,9,11,13-heptaen-2-ylidene}propyl)amine
SMILES
CN(C)CCC=C1C2=CC=CC=C2C=CC2=CC=CC=C12

Pharmacology

Indication

For use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.

Structured Indications
Pharmacodynamics

Cyclobenzaprine, closely related to the antidepressant amitriptyline, is used as a skeletal muscle relaxant to reduce pain and tenderness and improve mobility. Unlike dantrolene, cyclobenzaprine cannot be used to treat muscle spasm secondary to cerebral or spinal cord disease.

Mechanism of action

Like other tricyclic antidepressants, cyclobenzaprine exhibits anticholinergic activity, potentiation of norepinephrine, and antagonism of reserpine. Cyclobenzaprine does not directly act on the neuromuscular junction or the muscle but relieves muscle spasms through a central action, possibly at the brain stem level. Cyclobenzaprine binds to the serotonin receptor and is considered a 5-HT2 receptor antagonist that reduces muscle tone by decreasing the activity of descending serotonergic neurons.

TargetActionsOrganism
A5-hydroxytryptamine receptor 2A
antagonist
Human
Absorption

Slowly but well absorbed after oral administration

Volume of distribution
Not Available
Protein binding

Very high (93%)

Metabolism

Extensively metabolized (gastrointestinal and hepatic).

Route of elimination

Cyclobenzaprine is extensively metabolized, and is excreted primarily as glucuronides via the kidney.

Half life

18 hours (range 8-37 hours)

Clearance
  • 0.7 L/min
Toxicity

Oral mouse and rat LD50 are 338 mg/kg and 425 mg/kg respectively. Signs of overdose include agitation, coma, confusion, congestive heart failure, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high or low temperature, increased heartbeats, irregular heart rhythms, muscle stiffness, overactive reflexes, severe low blood pressure, stupor, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Cyclobenzaprine can be increased when it is combined with 1,10-Phenanthroline.Experimental
2,5-Dimethoxy-4-ethylamphetamineCyclobenzaprine may increase the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Cyclobenzaprine can be increased when it is combined with 3,4-Dichloroisocoumarin.Experimental
3,4-MethylenedioxyamphetamineCyclobenzaprine may increase the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Cyclobenzaprine can be increased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
4-Bromo-2,5-dimethoxyamphetamineCyclobenzaprine may increase the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineCyclobenzaprine may decrease the antihypertensive activities of 4-Methoxyamphetamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with 7-Nitroindazole.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineCyclobenzaprine may increase the serotonergic activities of 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AbirateroneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Abiraterone.Approved
AcenocoumarolCyclobenzaprine may increase the anticoagulant activities of Acenocoumarol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aceprometazine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Acetophenazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Adipiplon.Investigational
AgmatineCyclobenzaprine may decrease the antihypertensive activities of Agmatine.Experimental, Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Cyclobenzaprine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Allopregnanolone.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Cyclobenzaprine.Approved, Investigational
AlogliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Cyclobenzaprine can be increased when it is combined with Alpha-1-proteinase inhibitor.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Cyclobenzaprine.Approved, Illicit, Investigational
AltretamineAltretamine may increase the orthostatic hypotensive activities of Cyclobenzaprine.Approved
AmiodaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclobenzaprine.Approved
AmobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclobenzaprine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Amperozide.Experimental
AmphetamineCyclobenzaprine may increase the serotonergic activities of Amphetamine.Approved, Illicit
AmprenavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Amprenavir.Approved
Antithrombin III humanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Apixaban.Approved
ApomorphineCyclobenzaprine may decrease the antihypertensive activities of Apomorphine.Approved, Investigational
ApraclonidineCyclobenzaprine may decrease the antihypertensive activities of Apraclonidine.Approved
AprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Cyclobenzaprine can be increased when it is combined with Aprotinin.Approved, Withdrawn
ArbutamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arbutamine.Approved
ArformoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Arformoterol.Approved, Investigational
ArgatrobanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Argatroban.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Aripiprazole.Approved, Investigational
ArtemetherThe metabolism of Cyclobenzaprine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Asenapine.Approved
AsunaprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Asunaprevir.Approved, Investigational
AtazanavirThe metabolism of Cyclobenzaprine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Cyclobenzaprine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Azaperone.Investigational, Vet Approved
AzelastineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Azithromycin.Approved
BaclofenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Baclofen.Approved
BambuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bambuterol.Approved, Investigational
BarbexacloneThe metabolism of Cyclobenzaprine can be increased when combined with Barbexaclone.Experimental
BarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Barbital.Illicit
BatimastatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Batimastat.Experimental
BenazeprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benazepril.Approved, Investigational
BenmoxinCyclobenzaprine may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benperidol.Investigational
BenzamidineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Benzamidine.Experimental
BenzocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzocaine.Approved
BenzphetamineCyclobenzaprine may decrease the antihypertensive activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Benzyl alcohol.Approved
BetaxololThe metabolism of Cyclobenzaprine can be decreased when combined with Betaxolol.Approved
BethanidineCyclobenzaprine may decrease the antihypertensive activities of Bethanidine.Approved
BifeprunoxThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bifeprunox.Investigational
BivalirudinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe metabolism of Cyclobenzaprine can be decreased when combined with Boceprevir.Approved, Withdrawn
BortezomibThe metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
BrofaromineCyclobenzaprine may increase the serotonergic activities of Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromazepam.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromisoval.Experimental
BromocriptineCyclobenzaprine may decrease the antihypertensive activities of Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Bupivacaine.Approved, Investigational
BuprenorphineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Cyclobenzaprine can be decreased when combined with Bupropion.Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Cyclobenzaprine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclobenzaprine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butamben.Approved
ButaperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Cyclobenzaprine.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Cyclobenzaprine.Approved
CaffeineThe metabolism of Cyclobenzaprine can be decreased when combined with Caffeine.Approved
CamostatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Candoxatrilat.Experimental
CanertinibThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Canertinib.Investigational
CaptoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Cyclobenzaprine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Carisoprodol.Approved
CaroxazoneCyclobenzaprine may increase the serotonergic activities of Caroxazone.Withdrawn
CelecoxibThe metabolism of Cyclobenzaprine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Cyclobenzaprine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloroprocaine.Approved
ChloroquineThe metabolism of Cyclobenzaprine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorphenamine.Approved
ChlorphentermineCyclobenzaprine may increase the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorproethazine.Experimental
ChlorpromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Cyclobenzaprine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cholesterol.Experimental, Investigational
ChymostatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Chymostatin.Experimental
CilastatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cilazapril.Approved
CimetidineThe metabolism of Cyclobenzaprine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cinchocaine.Approved, Vet Approved
CirazolineCyclobenzaprine may increase the vasopressor activities of Cirazoline.Experimental
CitalopramThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Citalopram.Approved
ClarithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Cyclobenzaprine can be decreased when combined with Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clenbuterol.Approved, Investigational, Vet Approved
ClidiniumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clidinium.Approved
ClobazamThe metabolism of Cyclobenzaprine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clonazepam.Approved, Illicit
ClonidineCyclobenzaprine may decrease the antihypertensive activities of Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Cyclobenzaprine.Approved, Illicit
ClorindioneCyclobenzaprine may increase the anticoagulant activities of Clorindione.Experimental
ClothiapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Clothiapine.Experimental
ClotrimazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Cyclobenzaprine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Cyclobenzaprine can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Cyclobenzaprine.Approved, Illicit
ConivaptanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyclizine.Approved
CyclosporineThe metabolism of Cyclobenzaprine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cyclobenzaprine.Investigational
DarexabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Darexaban.Investigational
DarifenacinThe metabolism of Cyclobenzaprine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelanzomibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Delapril.Experimental
DelavirdineThe metabolism of Cyclobenzaprine can be decreased when combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desmopressin.Approved
DesvenlafaxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dexbrompheniramine.Approved
DexmedetomidineCyclobenzaprine may decrease the antihypertensive activities of Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe risk or severity of adverse effects can be increased when Dexmethylphenidate is combined with Cyclobenzaprine.Approved
DextroamphetamineCyclobenzaprine may increase the stimulatory activities of Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyclobenzaprine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Cyclobenzaprine.Approved, Illicit, Vet Approved
DicoumarolCyclobenzaprine may increase the anticoagulant activities of Dicoumarol.Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diethyl ether.Experimental
DiethylpropionCyclobenzaprine may increase the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineCyclobenzaprine may decrease the antihypertensive activities of Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Cyclobenzaprine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dimenhydrinate.Approved
DiphenadioneCyclobenzaprine may increase the anticoagulant activities of Diphenadione.Experimental
DiphenhydramineThe metabolism of Cyclobenzaprine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Diphenoxylate.Approved, Illicit
DipivefrinCyclobenzaprine may decrease the antihypertensive activities of Dipivefrin.Approved
DixyrazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dixyrazine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dobutamine.Approved
DolasetronDolasetron may increase the serotonergic activities of Cyclobenzaprine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doramectin.Vet Approved
DosulepinThe metabolism of Cyclobenzaprine can be decreased when combined with Dosulepin.Approved
DoxepinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Doxepin.Approved
DoxycyclineThe metabolism of Cyclobenzaprine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Illicit
DronedaroneThe metabolism of Cyclobenzaprine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Drotebanol.Experimental, Illicit
DroxidopaCyclobenzaprine may decrease the antihypertensive activities of Droxidopa.Approved, Investigational
DuloxetineDuloxetine may increase the serotonergic activities of Cyclobenzaprine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Dyclonine.Approved
EcabetThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ecabet.Approved, Investigational
EcgonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ecopipam.Investigational
EdoxabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Edoxaban.Approved
EfavirenzThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Elafin.Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Cyclobenzaprine.Approved, Investigational
EliglustatThe metabolism of Cyclobenzaprine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Eltanolone.Investigational
EnalaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Cyclobenzaprine can be increased when it is combined with Enalkiren.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Enflurane.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Enzalutamide.Approved
EphedraCyclobenzaprine may decrease the antihypertensive activities of Ephedra.Approved, Nutraceutical, Withdrawn
Epigallocatechin GallateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Epigallocatechin Gallate.Investigational
EpinephrineCyclobenzaprine may decrease the antihypertensive activities of Epinephrine.Approved, Vet Approved
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ergonovine.Approved
ErgotamineCyclobenzaprine may decrease the antihypertensive activities of Ergotamine.Approved
ErythromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Cyclobenzaprine.Approved
EthanolCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethotoin.Approved
Ethyl biscoumacetateCyclobenzaprine may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl chloride.Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etizolam.Approved
EtomidateCyclobenzaprine may decrease the antihypertensive activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ezogabine.Approved
FaldaprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Faldaprevir.Investigational
FelbamateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fenoterol.Approved, Investigational
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Cyclobenzaprine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluanisone.Experimental
FluconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fludiazepam.Approved, Illicit
FluindioneCyclobenzaprine may increase the anticoagulant activities of Fluindione.Investigational
FlunarizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclobenzaprine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Cyclobenzaprine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Cyclobenzaprine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Cyclobenzaprine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Cyclobenzaprine.Approved, Investigational
FormoterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Formoterol.Approved, Investigational
FosamprenavirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Cyclobenzaprine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Fospropofol.Approved, Illicit, Investigational
FrovatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Frovatriptan.Approved, Investigational
FurazolidoneCyclobenzaprine may increase the serotonergic activities of Furazolidone.Approved, Investigational, Vet Approved
Fusidic AcidThe serum concentration of Cyclobenzaprine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gabapentin Enacarbil.Approved
GabexateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Gabexate.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GeldanamycinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Geldanamycin.Experimental, Investigational
GepefrineCyclobenzaprine may increase the stimulatory activities of Gepefrine.Experimental
GepironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Glutethimide.Approved, Illicit
GM6001The serum concentration of Cyclobenzaprine can be increased when it is combined with GM6001.Experimental
GranisetronGranisetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
GuanabenzCyclobenzaprine may decrease the antihypertensive activities of Guanabenz.Approved, Investigational
GuanfacineCyclobenzaprine may decrease the antihypertensive activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Cyclobenzaprine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Halothane.Approved, Vet Approved
HarmalineCyclobenzaprine may increase the serotonergic activities of Harmaline.Experimental
HeroinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Heroin.Approved, Illicit, Investigational
HexobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Hexobarbital.Approved
HydracarbazineCyclobenzaprine may increase the serotonergic activities of Hydracarbazine.Experimental
HydrocodoneCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Cyclobenzaprine.Approved, Illicit
HydroxyamphetamineCyclobenzaprine may increase the stimulatory activities of Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
IdelalisibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Idelalisib.Approved
IdraparinuxThe serum concentration of Cyclobenzaprine can be increased when it is combined with Idraparinux.Investigational
IloperidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Iloperidone.Approved
ImatinibThe metabolism of Cyclobenzaprine can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Imidapril.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Cyclobenzaprine.Approved
IndacaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indacaterol.Approved
IndalpineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indalpine.Investigational, Withdrawn
IndinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Indinavir.Approved
IndiplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Indiplon.Investigational
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Cyclobenzaprine.Approved, Investigational
Iofetamine I-123Cyclobenzaprine may increase the stimulatory activities of Iofetamine I-123.Approved
IproclozideCyclobenzaprine may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidCyclobenzaprine may increase the serotonergic activities of Iproniazid.Withdrawn
IsavuconazoniumThe metabolism of Cyclobenzaprine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidCyclobenzaprine may increase the serotonergic activities of Isocarboxazid.Approved
IsoetarineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclobenzaprine.Approved, Vet Approved
IsoflurophateThe serum concentration of Cyclobenzaprine can be increased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsoniazidThe metabolism of Cyclobenzaprine can be decreased when combined with Isoniazid.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Isoprenaline.Approved
IsradipineThe metabolism of Cyclobenzaprine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ixazomib.Approved
KetamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ketobemidone.Approved, Investigational
KetoconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lamotrigine.Approved, Investigational
LepirudinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Letaxaban.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levobupivacaine.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levomilnacipran.Approved
LevonordefrinCyclobenzaprine may decrease the antihypertensive activities of Levonordefrin.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Cyclobenzaprine.Approved
LevosalbutamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Levosalbutamol.Approved
LevothyroxineLevothyroxine may increase the arrhythmogenic activities of Cyclobenzaprine.Approved
LidocaineThe metabolism of Cyclobenzaprine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Linagliptin.Approved
LinezolidLinezolid may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
LiothyronineLiothyronine may increase the arrhythmogenic activities of Cyclobenzaprine.Approved, Vet Approved
LiotrixLiotrix may increase the arrhythmogenic activities of Cyclobenzaprine.Approved
LisdexamfetamineCyclobenzaprine may increase the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Lisinopril.Approved, Investigational
LithiumLithium may increase the neurotoxic activities of Cyclobenzaprine.Approved
LobeglitazoneThe metabolism of Cyclobenzaprine can be decreased when combined with Lobeglitazone.Approved, Investigational
LofentanilThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lofentanil.Illicit
LofexidineCyclobenzaprine may decrease the antihypertensive activities of Lofexidine.Approved, Investigational
LopinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Lopinavir.Approved
LoprazolamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Cyclobenzaprine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lormetazepam.Approved
LovastatinThe metabolism of Cyclobenzaprine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Cyclobenzaprine.Approved
LuliconazoleThe serum concentration of Cyclobenzaprine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Cyclobenzaprine can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Cyclobenzaprine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Vet Approved
ManidipineThe metabolism of Cyclobenzaprine can be decreased when combined with Manidipine.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Maprotiline.Approved
MebanazineCyclobenzaprine may increase the serotonergic activities of Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Medetomidine.Vet Approved
MelagatranThe serum concentration of Cyclobenzaprine can be increased when it is combined with Melagatran.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Melperone.Approved, Investigational
MephedroneCyclobenzaprine may increase the stimulatory activities of Mephedrone.Investigational
MephentermineCyclobenzaprine may increase the vasopressor activities of Mephentermine.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Cyclobenzaprine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mesoridazine.Approved, Investigational
MetaraminolCyclobenzaprine may increase the vasopressor activities of Metaraminol.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Cyclobenzaprine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineCyclobenzaprine may decrease the antihypertensive activities of Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe metabolism of Cyclobenzaprine can be increased when combined with Methohexital.Approved
MethotrimeprazineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxamineCyclobenzaprine may increase the vasopressor activities of Methoxamine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineCyclobenzaprine may increase the stimulatory activities of Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methylecgonine.Experimental
Methylene blueCyclobenzaprine may increase the serotonergic activities of Methylene blue.Approved, Investigational
MethylphenidateThe risk or severity of adverse effects can be increased when Methylphenidate is combined with Cyclobenzaprine.Approved, Investigational
MethylphenobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Methylphenobarbital.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Cyclobenzaprine.Approved, Investigational
MetoprololThe metabolism of Cyclobenzaprine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineCyclobenzaprine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Cyclobenzaprine can be decreased when combined with Mexiletine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Cyclobenzaprine.Approved, Illicit
MidodrineCyclobenzaprine may increase the vasopressor activities of Midodrine.Approved
MidomafetamineCyclobenzaprine may increase the stimulatory activities of Midomafetamine.Experimental, Illicit, Investigational
MidostaurinThe metabolism of Cyclobenzaprine can be decreased when combined with Midostaurin.Approved
MifepristoneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Milnacipran.Approved
MinaprineCyclobenzaprine may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Investigational
MirabegronThe metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.Approved
MirtazapineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Mitotane.Approved
MMDACyclobenzaprine may increase the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideCyclobenzaprine may increase the serotonergic activities of Moclobemide.Approved
MoexiprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Moexipril.Approved
MolindoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Molindone.Approved
MoperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Moperone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Cyclobenzaprine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Mosapramine.Experimental
MoxonidineThe therapeutic efficacy of Moxonidine can be decreased when used in combination with Cyclobenzaprine.Approved, Investigational
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Cyclobenzaprine can be increased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved, Investigational
NafamostatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Nafamostat.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Cyclobenzaprine.Approved
NaphazolineCyclobenzaprine may decrease the antihypertensive activities of Naphazoline.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Naratriptan.Approved, Investigational
NefazodoneThe metabolism of Cyclobenzaprine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Cyclobenzaprine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Cyclobenzaprine can be increased when combined with Nevirapine.Approved
NialamideCyclobenzaprine may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe metabolism of Cyclobenzaprine can be decreased when combined with Nicardipine.Approved
NicorandilCyclobenzaprine may increase the hypotensive activities of Nicorandil.Approved, Investigational
NilotinibThe metabolism of Cyclobenzaprine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrazepam.Approved
NitroaspirinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Nitroaspirin.Investigational
Nitrous oxideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Nitrous oxide.Approved, Vet Approved
NorepinephrineCyclobenzaprine may decrease the antihypertensive activities of Norepinephrine.Approved
NorfluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclobenzaprine.Approved
OctamoxinCyclobenzaprine may increase the serotonergic activities of Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclobenzaprine.Approved, Investigational
OlaparibThe metabolism of Cyclobenzaprine can be decreased when combined with Olaparib.Approved
OlodaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olodaterol.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Olopatadine.Approved
OmapatrilatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Omapatrilat.Investigational
OndansetronOndansetron may increase the serotonergic activities of Cyclobenzaprine.Approved
OpiumThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Orciprenaline.Approved
OrphenadrineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Osimertinib.Approved
OtamixabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Otamixaban.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Cyclobenzaprine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxybuprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Cyclobenzaprine.Approved, Illicit, Investigational
OxymetazolineCyclobenzaprine may decrease the antihypertensive activities of Oxymetazoline.Approved
OxymorphoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Oxypertine.Experimental
PalbociclibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Palbociclib.Approved
PaliperidoneCyclobenzaprine may decrease the antihypertensive activities of Paliperidone.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
PanobinostatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Panobinostat.Approved, Investigational
ParaldehydeCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
PargylineCyclobenzaprine may increase the serotonergic activities of Pargyline.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclobenzaprine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenfluridolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Cyclobenzaprine.Approved, Vet Approved
PentobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
PerazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perazine.Investigational
PergolideCyclobenzaprine may decrease the antihypertensive activities of Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Perindopril.Approved
PerospironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Cyclobenzaprine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Cyclobenzaprine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenazocine.Experimental
PhenelzineCyclobenzaprine may increase the serotonergic activities of Phenelzine.Approved
PhenibutThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenibut.Experimental
PhenindioneCyclobenzaprine may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazineCyclobenzaprine may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Phenobarbital.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenoxyethanol.Approved
PhenoxypropazineCyclobenzaprine may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenprocoumonCyclobenzaprine may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentermineCyclobenzaprine may increase the stimulatory activities of Phentermine.Approved, Illicit
PhenylephrineCyclobenzaprine may increase the vasopressor activities of Phenylephrine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Cyclobenzaprine can be increased when combined with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Cyclobenzaprine can be increased when it is combined with Phosphoramidon.Experimental
PimozideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pimozide.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pipotiazine.Approved, Investigational
PirbuterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pirbuterol.Approved
PiritramideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Piritramide.Investigational
PirlindoleCyclobenzaprine may increase the serotonergic activities of Pirlindole.Approved
PivhydrazineCyclobenzaprine may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleCyclobenzaprine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Cyclobenzaprine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prilocaine.Approved
PrimidoneThe metabolism of Cyclobenzaprine can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Prinomastat.Investigational
ProcaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineCyclobenzaprine may increase the serotonergic activities of Procarbazine.Approved
ProcaterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Procaterol.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Cyclobenzaprine.Approved, Vet Approved
PromazineThe metabolism of Cyclobenzaprine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Proparacaine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propericiazine.Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Cyclobenzaprine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Cyclobenzaprine.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with PSD502.Investigational
PseudoephedrineCyclobenzaprine may decrease the antihypertensive activities of Pseudoephedrine.Approved
QuazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quetiapine.Approved
QuinaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Quinapril.Approved, Investigational
QuinidineCyclobenzaprine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineThe metabolism of Cyclobenzaprine can be decreased when combined with Quinine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Quinisocaine.Experimental
RacecadotrilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Racecadotril.Investigational
RacloprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ramelteon.Approved, Investigational
RamiprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Cyclobenzaprine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineCyclobenzaprine may increase the serotonergic activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Cyclobenzaprine.Approved
RemikirenThe serum concentration of Cyclobenzaprine can be increased when it is combined with Remikiren.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Remoxipride.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Cyclobenzaprine.Approved, Investigational
RifabutinThe metabolism of Cyclobenzaprine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Cyclobenzaprine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Cyclobenzaprine can be increased when combined with Rifapentine.Approved
RisperidoneCyclobenzaprine may decrease the antihypertensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritanserin.Investigational
RitobegronCyclobenzaprine may increase the stimulatory activities of Ritobegron.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ritodrine.Approved, Investigational
RitonavirThe metabolism of Cyclobenzaprine can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Rivaroxaban.Approved
RizatriptanThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Rizatriptan.Approved
RolapitantThe metabolism of Cyclobenzaprine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Romifidine.Vet Approved
RopiniroleCyclobenzaprine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ropivacaine.Approved
RotigotineCyclobenzaprine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Cyclobenzaprine.Approved
S-3304The serum concentration of Cyclobenzaprine can be increased when it is combined with S-3304.Investigational
SafrazineCyclobenzaprine may increase the serotonergic activities of Safrazine.Withdrawn
SalbutamolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salbutamol.Approved, Vet Approved
SalmeterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Salmeterol.Approved
SaquinavirThe metabolism of Cyclobenzaprine can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Saxagliptin.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Cyclobenzaprine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineCyclobenzaprine may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Cyclobenzaprine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Cyclobenzaprine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Cyclobenzaprine can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Cyclobenzaprine can be increased when it is combined with Sivelestat.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
Sodium phosphateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sodium phosphate.Approved
SpiraprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Spirapril.Approved
St. John's WortThe metabolism of Cyclobenzaprine can be increased when combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Cyclobenzaprine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.Approved, Investigational
SulfisoxazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sulpiride.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Sultopride.Experimental
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Cyclobenzaprine.Approved, Investigational
SuvorexantCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Cyclobenzaprine.Approved
TelaprevirThe metabolism of Cyclobenzaprine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelithromycinThe metabolism of Cyclobenzaprine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Cyclobenzaprine.Approved
TemocaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Cyclobenzaprine can be decreased when combined with Tenofovir disoproxil.Approved, Investigational
TerbinafineThe metabolism of Cyclobenzaprine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Terbutaline.Approved
TeriflunomideThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tetrodotoxin.Investigational
ThalidomideCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Cyclobenzaprine can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Cyclobenzaprine can be increased when combined with Thiamylal.Approved, Vet Approved
ThiopentalThe metabolism of Cyclobenzaprine can be increased when combined with Thiopental.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thioproperazine.Approved
ThioridazineThe metabolism of Cyclobenzaprine can be decreased when combined with Thioridazine.Approved, Withdrawn
ThiorphanThe serum concentration of Cyclobenzaprine can be increased when it is combined with Thiorphan.Experimental
ThiothixeneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Thiothixene.Approved
Thyroid, porcineThyroid, porcine may increase the arrhythmogenic activities of Cyclobenzaprine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiapride.Approved, Investigational
TiclopidineThe metabolism of Cyclobenzaprine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tilidine.Experimental
TioclomarolCyclobenzaprine may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirThe metabolism of Cyclobenzaprine can be decreased when combined with Tipranavir.Approved, Investigational
TizanidineCyclobenzaprine may decrease the antihypertensive activities of Tizanidine.Approved
TocilizumabThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Tocilizumab.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneCyclobenzaprine may increase the serotonergic activities of Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Topiramate.Approved
TramadolCyclobenzaprine may increase the neuroexcitatory activities of Tramadol.Approved, Investigational
TrandolaprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Trandolapril.Approved
Trans-2-PhenylcyclopropylamineCyclobenzaprine may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineCyclobenzaprine may increase the serotonergic activities of Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Cyclobenzaprine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Cyclobenzaprine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Cyclobenzaprine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triflupromazine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Cyclobenzaprine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Cyclobenzaprine.Approved, Investigational
UbenimexThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ulinastatin.Investigational
Valproic AcidThe serum concentration of Cyclobenzaprine can be increased when it is combined with Valproic Acid.Approved, Investigational
VemurafenibThe serum concentration of Cyclobenzaprine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Cyclobenzaprine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Veralipride.Experimental
VerapamilThe metabolism of Cyclobenzaprine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vigabatrin.Approved
VilanterolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vilanterol.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Cyclobenzaprine.Approved
VildagliptinThe serum concentration of Cyclobenzaprine can be increased when it is combined with Vildagliptin.Approved, Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vinyl ether.Experimental
VoriconazoleThe metabolism of Cyclobenzaprine can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyclobenzaprine.Approved
WarfarinCyclobenzaprine may increase the anticoagulant activities of Warfarin.Approved
XenonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Xenon.Experimental
XimelagatranThe serum concentration of Cyclobenzaprine can be increased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Xylazine.Vet Approved
XylometazolineCyclobenzaprine may decrease the antihypertensive activities of Xylometazoline.Approved
YohimbineThe serum concentration of Yohimbine can be increased when it is combined with Cyclobenzaprine.Approved, Vet Approved
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Cyclobenzaprine can be increased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZaleplonThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Cyclobenzaprine can be decreased when combined with Ziprasidone.Approved
ZofenoprilThe serum concentration of Cyclobenzaprine can be increased when it is combined with Zofenopril.Experimental
ZolazepamThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Cyclobenzaprine.Approved, Investigational
ZolpidemCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zotepine.Approved, Investigational
ZucapsaicinThe metabolism of Cyclobenzaprine can be decreased when combined with Zucapsaicin.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food to reduce irritation.

References

Synthesis Reference

Villani, F.J.; US. Patent 3,409,640; November 5,1968; assigned to Schering Corporation.

General References
Not Available
External Links
Human Metabolome Database
HMDB15060
KEGG Compound
C06931
PubChem Compound
2895
PubChem Substance
46508313
ChemSpider
2792
BindingDB
112774
ChEBI
3996
ChEMBL
CHEMBL669
Therapeutic Targets Database
DAP000891
PharmGKB
PA449160
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Cyclobenzaprine
ATC Codes
M03BX08 — Cyclobenzaprine
AHFS Codes
  • 12:20.04 — Centrally Acting Skeletal Muscle Relaxants
FDA label
Download (230 KB)
MSDS
Download (73.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentHealthy Adults3
2CompletedTreatmentCervical Strain1
2TerminatedSupportive CarePain / Sleep Initiation and Maintenance Disorders1
3CompletedTreatmentBack Pain / Cervical Pain / Spasms1
3CompletedTreatmentFibromyalgia, Primary1
3Not Yet RecruitingTreatmentLiver Cirrhosis1
3Not Yet RecruitingTreatmentPain, Acute1
3Not Yet RecruitingTreatmentPainful musculoskeletal conditions1
3TerminatedPreventionChronic Migraine1
3TerminatedTreatmentFibromyalgia, Primary1
4CompletedTreatmentPain / Spasms1
4Unknown StatusTreatmentAcute Low Back Pain1
4Unknown StatusTreatmentFibromyalgia / Pain / Sleep / Tiredness1
Not AvailableCompletedNot AvailableHealthy Volunteers1
Not AvailableCompletedBasic ScienceUrethral Sphincter Activity1
Not AvailableCompletedTreatmentTemporomandibular Disorders1
Not AvailableEnrolling by InvitationNot AvailableArthritis / Gout Acute / Headaches / Migraines / Muscle Spasms / Radicular syndrome / Synovitis / Tendonitis1
Not AvailableUnknown StatusTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
  • Anesta ag
  • Actavis totowa llc
  • Aurobindo pharma ltd
  • Cadista pharmaceuticals inc
  • Invagen pharmaceuticals inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Orit laboratories llc
  • Pliva inc
  • Ranbaxy laboratories ltd
  • Sandoz inc
  • Vintage pharmaceuticals inc
  • Watson laboratories inc
  • Mcneil pediatrics
Packagers
Dosage forms
FormRouteStrength
Capsule, extended releaseOral15 mg/1
Capsule, extended releaseOral30 mg/1
Kit
Capsule, film coated, extended releaseOral10 mg/1
Capsule, film coated, extended releaseOral5 mg/1
TabletOral10 mg/1
TabletOral10 mg/10mg
TabletOral5 mg/1
TabletOral7.5 mg/1
Tablet, film coatedOral10 mg/301
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral5 mg/1
Tablet, film coatedOral7.5 mg/1
Kit
KitTopical
TabletOral10 mg
KitOral
Prices
Unit descriptionCostUnit
Cyclobenzaprine hcl crystal273.88USD g
Cyclobenzaprine hcl powder35.84USD g
Fexmid 7.5 mg tablet4.18USD tablet
Flexeril 5 mg tablet2.04USD tablet
Flexeril 10 mg tablet1.74USD tablet
Cyclobenzaprine HCl 5 mg tablet1.71USD tablet
Cyclobenzaprine 5 mg tablet1.64USD tablet
Cyclobenzaprine HCl 10 mg tablet0.47USD tablet
Cyclobenzaprine 10 mg tablet0.41USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7544372No2003-11-142023-11-14Us
US7829121No2003-11-142023-11-14Us
US7820203No2003-11-142023-11-14Us
US7790199No2003-11-142023-11-14Us
US7387793No2005-02-262025-02-26Us
US9399025No2003-11-142023-11-14Us
US9375410No2003-11-142023-11-14Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
boiling point (°C)173-177Not Available
water solubilityFreely SolubleNot Available
logP5.2Not Available
pKa8.47Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00689 mg/mLALOGPS
logP4.73ALOGPS
logP4.61ChemAxon
logS-4.6ALOGPS
pKa (Strongest Basic)9.76ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area3.24 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity102.62 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9941
Blood Brain Barrier+0.9512
Caco-2 permeable+0.8867
P-glycoprotein substrateSubstrate0.7567
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6447
Renal organic cation transporterInhibitor0.7955
CYP450 2C9 substrateNon-substrate0.7826
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateSubstrate0.7501
CYP450 1A2 substrateInhibitor0.7324
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8933
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.9158
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6955
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.8127
BiodegradationNot ready biodegradable0.8727
Rat acute toxicity2.9697 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.7531
hERG inhibition (predictor II)Inhibitor0.6767
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as dibenzocycloheptenes. These are compounds containing a dibenzocycloheptene moiety, which consists of two benzene rings connected by a cycloheptene ring.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Dibenzocycloheptenes
Sub Class
Not Available
Direct Parent
Dibenzocycloheptenes
Alternative Parents
Trialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Dibenzocycloheptene / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine / Aromatic homopolycyclic compound
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
organic tricyclic compound (CHEBI:3996)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Honda M, Nishida T, Ono H: Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors. Eur J Pharmacol. 2003 Jan 1;458(1-2):91-9. [PubMed:12498911]
  2. Kobayashi H, Hasegawa Y, Ono H: Cyclobenzaprine, a centrally acting muscle relaxant, acts on descending serotonergic systems. Eur J Pharmacol. 1996 Sep 5;311(1):29-35. [PubMed:8884233]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Wang RW, Liu L, Cheng H: Identification of human liver cytochrome P450 isoforms involved in the in vitro metabolism of cyclobenzaprine. Drug Metab Dispos. 1996 Jul;24(7):786-91. [PubMed:8818577]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:33